Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
2341 | 2275 | 35.2 | 62% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
316 | 3 | RHEUMATOLOGY//RHEUMATOID ARTHRITIS//RHEUMATOL | 39766 |
1684 | 2 | METHOTREXATE//FOLATE RECEPTOR//REDUCED FOLATE CARRIER | 6769 |
2341 | 1 | REDUCED FOLATE CARRIER//FOLYLPOLYGLUTAMATE SYNTHETASE//ANTIFOLATE | 2275 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | REDUCED FOLATE CARRIER | authKW | 728976 | 4% | 64% | 85 |
2 | FOLYLPOLYGLUTAMATE SYNTHETASE | authKW | 485971 | 2% | 77% | 47 |
3 | ANTIFOLATE | authKW | 481567 | 5% | 33% | 109 |
4 | PROTON COUPLED FOLATE TRANSPORTER | authKW | 276868 | 1% | 74% | 28 |
5 | PCFT | authKW | 253540 | 1% | 82% | 23 |
6 | HEREDITARY FOLATE MALABSORPTION | authKW | 228146 | 1% | 100% | 17 |
7 | EXPT CLIN THER EUT PROGRAM | address | 214701 | 1% | 57% | 28 |
8 | FOLATE TRANSPORT | authKW | 209674 | 1% | 63% | 25 |
9 | EDATREXATE | authKW | 185096 | 1% | 69% | 20 |
10 | POLYGLUTAMATION | authKW | 176287 | 1% | 77% | 17 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 8092 | 32% | 0% | 722 |
2 | Chemistry, Medicinal | 3095 | 12% | 0% | 262 |
3 | Pharmacology & Pharmacy | 2552 | 21% | 0% | 486 |
4 | Biochemistry & Molecular Biology | 1266 | 23% | 0% | 524 |
5 | Chemistry, Organic | 376 | 7% | 0% | 169 |
6 | Biophysics | 265 | 5% | 0% | 114 |
7 | Hematology | 221 | 4% | 0% | 87 |
8 | Biochemical Research Methods | 71 | 3% | 0% | 65 |
9 | Medicine, Research & Experimental | 60 | 3% | 0% | 72 |
10 | Nutrition & Dietetics | 58 | 2% | 0% | 45 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | EXPT CLIN THER EUT PROGRAM | 214701 | 1% | 57% | 28 |
2 | PROGRAM MOL PHARMACOL EXPT THER EUT | 94346 | 1% | 47% | 15 |
3 | FRED WYSZKOWSKI CANC | 57862 | 1% | 25% | 17 |
4 | PENNY COLE HEMATOL | 42943 | 0% | 80% | 4 |
5 | GRACE CANC DRUG | 39397 | 1% | 12% | 24 |
6 | ALBERT E EIN COMPREHENS CANC | 30656 | 1% | 19% | 12 |
7 | GRACE CANC DRUG EXPTL THER EUT | 26841 | 0% | 100% | 2 |
8 | MOLEC THER EUT | 26841 | 0% | 100% | 2 |
9 | TAKEDA RABICS | 26841 | 0% | 100% | 2 |
10 | MOL THER EUT PROGRAM | 19058 | 1% | 9% | 16 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | ADVANCES IN ENZYME REGULATION | 17600 | 1% | 5% | 28 |
2 | JOURNAL OF MEDICINAL CHEMISTRY | 17508 | 7% | 1% | 168 |
3 | CANCER CHEMOTHERAPY AND PHARMACOLOGY | 15040 | 4% | 1% | 91 |
4 | BIOCHEMICAL PHARMACOLOGY | 10856 | 5% | 1% | 123 |
5 | CANCER RESEARCH | 7886 | 7% | 0% | 153 |
6 | INVESTIGATIONAL NEW DRUGS | 5333 | 1% | 1% | 32 |
7 | MOLECULAR PHARMACOLOGY | 3783 | 2% | 1% | 53 |
8 | CLINICAL CANCER RESEARCH | 3611 | 3% | 0% | 64 |
9 | CANCER DRUG DELIVERY | 2883 | 0% | 4% | 5 |
10 | VITAMINS AND HORMONES-ADVANCES IN RESEARCH AND APPLICATIONS | 2299 | 0% | 2% | 8 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | REDUCED FOLATE CARRIER | 728976 | 4% | 64% | 85 | Search REDUCED+FOLATE+CARRIER | Search REDUCED+FOLATE+CARRIER |
2 | FOLYLPOLYGLUTAMATE SYNTHETASE | 485971 | 2% | 77% | 47 | Search FOLYLPOLYGLUTAMATE+SYNTHETASE | Search FOLYLPOLYGLUTAMATE+SYNTHETASE |
3 | ANTIFOLATE | 481567 | 5% | 33% | 109 | Search ANTIFOLATE | Search ANTIFOLATE |
4 | PROTON COUPLED FOLATE TRANSPORTER | 276868 | 1% | 74% | 28 | Search PROTON+COUPLED+FOLATE+TRANSPORTER | Search PROTON+COUPLED+FOLATE+TRANSPORTER |
5 | PCFT | 253540 | 1% | 82% | 23 | Search PCFT | Search PCFT |
6 | HEREDITARY FOLATE MALABSORPTION | 228146 | 1% | 100% | 17 | Search HEREDITARY+FOLATE+MALABSORPTION | Search HEREDITARY+FOLATE+MALABSORPTION |
7 | FOLATE TRANSPORT | 209674 | 1% | 63% | 25 | Search FOLATE+TRANSPORT | Search FOLATE+TRANSPORT |
8 | EDATREXATE | 185096 | 1% | 69% | 20 | Search EDATREXATE | Search EDATREXATE |
9 | POLYGLUTAMATION | 176287 | 1% | 77% | 17 | Search POLYGLUTAMATION | Search POLYGLUTAMATION |
10 | TRIMETREXATE | 161276 | 1% | 48% | 25 | Search TRIMETREXATE | Search TRIMETREXATE |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | GONEN, N , ASSARAF, YG , (2012) ANTIFOLATES IN CANCER THERAPY: STRUCTURE, ACTIVITY AND MECHANISMS OF DRUG RESISTANCE.DRUG RESISTANCE UPDATES. VOL. 15. ISSUE 4. P. 183 -210 | 223 | 62% | 85 |
2 | MATHERLY, LH , WILSON, MR , HOU, ZJ , (2014) THE MAJOR FACILITATIVE FOLATE TRANSPORTERS SOLUTE CARRIER 19A1 AND SOLUTE CARRIER 46A1: BIOLOGY AND ROLE IN ANTIFOLATE CHEMOTHERAPY OF CANCER.DRUG METABOLISM AND DISPOSITION. VOL. 42. ISSUE 4. P. 632 -649 | 162 | 78% | 6 |
3 | ZHAO, RB , GOLDMAN, ID , (2003) RESISTANCE TO ANTIFOLATES.ONCOGENE. VOL. 22. ISSUE 47. P. 7431-7457 | 195 | 64% | 145 |
4 | HOU, ZJ , MATHERLY, LH , (2014) BIOLOGY OF THE MAJOR FACILITATIVE FOLATE TRANSPORTERS SLC19A1 AND SLC46A1.EXCHANGERS. VOL. 73. ISSUE . P. 175 -204 | 108 | 87% | 16 |
5 | ASSARAF, YG , (2007) MOLECULAR BASIS OF ANTIFOLATE RESISTANCE.CANCER AND METASTASIS REVIEWS. VOL. 26. ISSUE 1. P. 153-181 | 143 | 66% | 141 |
6 | MCGUIRE, JJ , (2003) ANTICANCER ANTIFOLATES: CURRENT STATUS AND FUTURE DIRECTIONS..CURRENT PHARMACEUTICAL DESIGN. VOL. 9. ISSUE 31. P. 2593 -2613 | 136 | 78% | 185 |
7 | MATHERLY, LH , GOLDMAN, D , (2003) MEMBRANE TRANSPORT OF FOLATES.VITAMINS AND HORMONES - ADVANCES IN RESEARCH AND APPLICATIONS, VOL 66. VOL. 66. ISSUE . P. 403 -456 | 139 | 59% | 227 |
8 | MATHERLY, LH , HOU, ZJ , DENG, YJ , (2007) HUMAN REDUCED FOLATE CARRIER: TRANSLATION OF BASIC BIOLOGY TO CANCER ETIOLOGY AND THERAPY.CANCER AND METASTASIS REVIEWS. VOL. 26. ISSUE 1. P. 111 -128 | 104 | 74% | 86 |
9 | RAZ, S , STARK, M , ASSARAF, YG , (2016) FOLYLPOLY-GAMMA-GLUTAMATE SYNTHETASE: A KEY DETERMINANT OF FOLATE HOMEOSTASIS AND ANTIFOLATE RESISTANCE IN CANCER.DRUG RESISTANCE UPDATES. VOL. 28. ISSUE . P. 43 -64 | 122 | 56% | 0 |
10 | DESMOULIN, SK , HOU, ZJ , GANGJEE, A , MATHERLY, LH , (2012) THE HUMAN PROTON-COUPLED FOLATE TRANSPORTER BIOLOGY AND THERAPEUTIC APPLICATIONS TO CANCER.CANCER BIOLOGY & THERAPY. VOL. 13. ISSUE 14. P. 1355-1373 | 94 | 63% | 28 |
Classes with closest relation at Level 1 |